<DOC>
	<DOC>NCT01898845</DOC>
	<brief_summary>This study will evaluate safety and tolerability to estimate the MTD and/or recommended dose for expansion.</brief_summary>
	<brief_title>A Phase I Study of LEE011 in Asian Patients</brief_title>
	<detailed_description>This is a multi-center, open label, dose finding, phase I study of oral single agent LEE011, administered once daily.</detailed_description>
	<criteria>Patient with a histologically confirmed diagnosis of a solid tumor ECOG PS &lt;2 Good organ function at screening visit A sufficient interval mast have elapsed between the last dose of prior anticancer therapy Impairment of GI function Patients with concurrent severe and/or uncontrolled concurrent medical conditions Known diagnosis of HIV or active viral hepatitis Pregnant or nursing (lactating) women</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>Neoplasms</keyword>
</DOC>